Phase 1 N=6 AMD 3100 for Treatment of Myelokathexis
Neutropenia
Primary: Blood Neutrophil Counts. — 4.48 10^9 per Liter — p=<0.05
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=99 Study Of PF-00562271, Including Patients With Pancreatic, Head And Neck, Prostatic Neoplasms
Head and Neck Neoplasm · Prostatic Neoplasm · Pancreatic Neoplasm
Primary: Number of Participants With First Cycle Dose Limiting Toxicities (DLTs) — 0; 0; 0; 0 participants
Phase 1 N=50 Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Adult (18-40 Years Old)
Typhoid Fever
Primary: Number of Subjects Reporting Any Post Immunization Reactions — 23; 16 participants
Phase 1 N=57 Phase 1 Study Of Aurora Kinase Inhibitor PF-03814735 In Patients With Advanced Solid Tumors
Solid Tumors
Primary: Number of Participants With First Cycle Dose Limiting Toxicities (DLTs) Graded According to Common Terminology Criteria Adverse Events (CTCAE), Version 3 — 0; 0; 0; 0…
Phase 1 N=133 Safety and Immune Response of Candidate H1N1 Influenza Vaccine GSK2340274A Following Seasonal Influenza Vaccination in Adults
Influenza
Primary: Number of Seroconverted Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain. — 21; 28; 25…
Phase 1 N=22 A Study On An Immunostimulant Antibody In Combination With Chemotherapy For Advanced Cancer Of The Pancreas
Pancreatic Neoplasm
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) — 0; 0; 1 participants
Phase 1 N=80 Abuse Potential of Orally Administered Crushed Embeda Compared to Crushed Controlled-Release Morphine and Placebo in Non-Dependent Recreational Opioid Users
Nondependent Opioid Abuse, Episodic
Primary: Drug Liking: Area Under Effect Curve (AUE) From 0-2 Hours — 88.3; 100.3; 124.7 hrs*mm — p=<0.0001
Phase 1 N=94 A Safety Study to Assess the Effects of Therapeutic and Supratherapeutic Exenatide Concentrations on QT Interval in Healthy Subjects
Healthy Subjects
Primary: Comparison of Least Squares (LS) Mean Changes From Baseline in Population-based Corrected QT Intervals (QTcP) Between Exenatide and Placebo on Day 1 Averaged Over 1300h…
Phase 1 N=6 A Study of Absorption, Metabolism, Excretion and Mass Balance After a Single Dose Administration of MK-0941 (MK-0941-016)(COMPLETED)
Type 2 Diabetes
Primary: Mean Percent of Dose Recovered in Urine and Feces Following a Single Oral Dose of [^14C]MK-0941 (160 µCi). — 60.0; 38.7 Percent Recovered
Phase 1 N=38 The Effects of Antihypertensive Agents on Central Blood Pressure in Healthy Participants and Participants With Hypertension (MK-0000-166) (COMPLETED)
Hypertension
Primary: Time-weighted Average (TWA) Change From Baseline (0 Hours) to 12 Hours in Heart-Rate-Corrected Augmentation Index (AIx) After A Single Dose of Treatment — -11.1; -0.7…
Phase 1 N=16 Early Airway Response to Allergen in Asthmatics (MK-0000-176)
Asthma
Primary: Change in Forced Expiratory Volume in 1 Second (FEV1) — -24.66; -8.44; -9.15; -16.17 Percentage drop in FEV1 — p=<0.0001
Phase 1 N=50 Safety, Tolerability, and Immunogenicity Study of a Clostridium Difficile Toxoid Vaccine in Healthy Adult Volunteers
Clostridium Infections
Primary: Number of Participants Reporting Solicited Injection Site Erythema and Tenderness Post-vaccination With Either One of Three Formulations of Clostridium Difficile…
Phase 1 N=24 A Study of Tadalafil in Benign Prostatic Hyperplasia
Benign Prostatic Hyperplasia
Primary: Pharmacokinetics: Area Under the Concentration Curve (AUC) for Tadalafil and Metabolite IC710 — 1410; 1340; 2710; 3410 nanograms*hour/milliliter (ng*hr/mL)
Phase 1 N=20 Performance and Safety Evaluation of an Intradermal Delivery Device
Injections, Intradermal
Primary: Proportion of Injections Delivered to the Intradermal Layer of the Skin — 1 percentage of injections
Phase 1 N=28 Telmisartan, Amlodipine and Combination in Healthy Subjects
Healthy
Primary: Area Under the Concentration-time Curve of Telmisartan in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Data Point (AUC_0-tz) — 3200; 2940…